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The KCL032 human embryonic stem cell linewas derived from a normal healthy blastocyst donated for research.
The ICM was isolated using laser microsurgery and plated on γ-irradiated human foreskin ﬁbroblasts. Both the
derivation and cell line propagation were performed in an animal product-free environment and under current
Good Manufacturing Practice (cGMP) standards. Pluripotent state and differentiation potential were conﬁrmed
by in vitro assays.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Resource table
Name of stem cell
line
KCL032
Institution King's College London, London UK
Derivation team
Neli Kadeva, Victoria Wood, Glenda Cornwell, Stefano
Codognotto, Emma Stephenson
Contact person
and email
Dusko Ilic, email: dusko.ilic@kcl.ac.uk
Date
archived/stock
date
Oct. 10, 2011
Type of resource Biological reagent: cell line
Sub-type Human pluripotent stem cell line
Origin Human embryo
Key marker
expression
Pluripotent stem cell markers: NANOG, OCT4, TRA-1-60,
TRA-1-81, alkaline phosphatase (AP) activity
Authentication Identity and purity of line conﬁrmed
Link to related
literature
(direct URL
links and full
references)
1) Jacquet, L., Stephenson, E., Collins, R., Patel, H., Trussler, J.,
Al-Bedaery, R., Renwick, P., Ogilvie, C., Vaughan, R., Ilic, D.,
2013. Strategy for the creation of clinical grade hESC line
banks that HLA-match a target population. EMBO Mol.
Med. 5 (1), 10–17.
doi: 10.1002/emmm.201201973
http://www.ncbi.nlm.nih.gov/pubmed/23161805
2) Canham, A., Van Deusen, A., Brison, D.R., De Sousa, P.,
Downie, J., Devito, L., Hewitt, Z.A., Ilic, D., Kimber, S.J.,
Moore, H.D., Murray, H., Kunath, T., 2015. The molecular
karyotype of 25 clinical-grade human embryonic stem
cells lines. Sci. Rep. 5, 17258.
doi: 10.1038/srep17258
3) Ilic, D., Stephenson, E., Wood, V., Jacquet, L., Stevenson, D.,
Petrova, A., Kadeva, N., Codognotto, S., Patel, H., Semple, M.,
Cornwell, G., Ogilvie, C., Braude, P., 2012. Derivation and
feeder-free propagation of human embryonic stem cells
under xeno-free conditions. Cytotherapy. 14 (1), 122–128.
doi: 10.3109/14653249.2011.623692
http://www.ncbi.nlm.nih.gov/pubmed/22029654
4) Stephenson, E., Jacquet, L., Miere, C., Wood, V., Kadeva, N.,
Cornwell, G., Codognotto, S., Dajani, Y., Braude, P., Ilic, D.,
2012. Derivation and propagation of human embryonic
stem cell lines from frozen embryos in an animal
product-free environment. Nat. Protoc. 7 (7), 1366–1381.
doi: 10.1038/nprot.2012.080
http://www.ncbi.nlm.nih.gov/pubmed/22722371
Information in
public
databases
KCL032 is a National Institutes of Health (NIH) registered hESC
line.
NIH registration number: NIHhESC-14-0266.
http://grants.nih.gov/stem_cells/registry/current.htm?id=652
Ethics
The hESC line KCL032 is derived under license from the UK
Human Fertilisation and Embryology Authority (research li-
cense numbers: R0075 and R0133) and also has local ethical
approval (UK National Health Service Research Ethics Com-
mittee Reference: 06/Q0702/90).
Informed consent was obtained from all subjects and the ex-
periments conformed to the principles set out in the WMA
Declaration of Helsinki and the NIH Belmont Report. No ﬁnan-
cial inducements are offered for donation.
2. Resource details
Consent signed May 26, 2009
Embryo thawed Jul. 11, 2011
UK stem cell bank deposit Sep. 13, 2012
(continued on next page)
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⁎ Corresponding author.
E-mail address: dusko.ilic@kcl.ac.uk (D. Ilic).
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Contents lists available at ScienceDirect
Stem Cell Research
j ourna l homepage: www.e lsev ie r .com/ locate /scr
approval Reference: SCSC12-37
Sex Female 46, XX
Grade Clinical
Disease status Healthy/unaffected
Karyotype (aCGH) Gain in region 5p14.3
SNP array Gain in region 5p14.3 (Canham et al., 2015)
DNA ﬁngerprint
Allele sizes (in bp) of 16 microsatellite markers
speciﬁc for chromosomes 13, 18 and 21 (Jacquet et al.,
2013)
HLA typing
HLA-A2,11; B51,62; Bw4,6; Cw4,9; DR4,13; DR52,53;
DQ6,7 (Jacquet et al., 2013)
Viability testing Pass
Mycoplasma Negative
Sterility Pass
Pluripotent markers
(immunostaining)
(Fig. 1)
NANOG, OCT4, TRA-1-60, TRA-1-81, AP activity
Three germ layers
differentiation in vitro
(immunostaining)
(Fig. 2)
Endoderm: AFP
Ectoderm: TUBB3 (tubulin, beta 3 class III)
Mesoderm: ACTA2 (actin, alpha 2, smooth muscle)
Sibling lines available KCL033, KCL034
We generated KCL032 clinical grade hESC line following protocols,
established previously (Ilic et al., 2012; Stephenson et al., 2012), and
now adapted to cGMP conditions. The expression of the pluripotency
markers was tested after freeze/thaw cycle (Fig. 1). Differentiation po-
tential into three germ layers was veriﬁed in vitro (Fig. 2).
Molecular karyotyping identiﬁed a novel 2.4 Mb gain on chromo-
some 5p14.3, containing a single gene, CDH18 (Cadherin-18), that was
also present in one of two sibling cell lines, KCL033, but not in KCL034,
a third sibling. A duplication of this size has not been reported to date,
but its presence in two sibling hESC lines strongly suggests that it was
inherited from one of the parents rather than by acquisition during
hESC derivation and culture (Canham et al., 2015). The 2498.8 bp gain
starts at bp 19,086,546 and ends at bp 21,585,311 as referred to
Human Genome Build 38.
We also generated research grade of KCL032 line that is adapted to
feeder-free conditions.
3. Materials and methods
3.1. Consenting process
We distribute Patient Information Sheet (PIS) and consent form to
the in vitro fertilization (IVF) patients if they opted to donate to research
embryos that were stored for 5 or 10 years. They mail signed consent
back to us and that might be months after the PIS and consent were
mailed to them. For in the meantime new versions of PIS/consent are
implemented, we do not send these to the patients or ask them to re-
sign; the whole process is done with the version that was given them
initially. The PIS/consent documents (FRO-V.6) were created on Dec.
18, 2008. HFEA Code of Practice that was in effect at the time of docu-
ment creation: Edition 7 — R.4 (http://www.hfea.gov.uk/2999.html).
The donor couple signed the consent on May 26, 2009. HFEA Code of
Practice that was in effect at the time of donor signature: Edition 7 —
R.4. HFEA Code of Practice Edition 7 — R.4 was in effect: 02 Oct. 2008–
30 Sep. 2009.
3.2. Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass
(ICM) were carried out as previously described in details (Ilic et al.,
2012; Stephenson et al., 2012). The cellular area containing the ICM
was then washed and transferred to plates containing mitotically
inactivated human neonatal foreskin ﬁbroblasts (HFF).
3.3. Cell culture
ICMplated onmitotically inactivatedHFFwere cultured as described
(Ilic et al., 2012; Stephenson et al., 2012). TE cells were removed me-
chanically fromoutgrowth (Ilic et al., 2007; Ilic et al., 2010). hES colonies
were expanded and cryopreserved at the third passage.
3.4. Viability test
Straws with the earliest frozen passage (p.2–3) are thawed and new
colonies are counted three days later. These colonies are then expanded
up to passage 8, atwhich point cellswere part frozen and part subjected
to standard battery of tests (pluripotency markers, in vitro and in vivo
differentiation capability, genetics, sterility, mycoplasma).
3.5. Pluripotency markers
Pluripotencywas assessed using two different techniques: enzymat-
ic activity assay [alkaline phosphatase (AP) assay] and immunostaining
as described (Ilic et al., 2012; Stephenson et al., 2012).
Fig. 1. Expression of pluripotency markers. Pluripotency is conﬁrmed by immunostaining (Oct4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Actin stress
ﬁbers, visualized with rhodamine-phalloidin (red), are present in both feeders and hES cell colonies, whereas AP activity (green) is detected only in hES cells. Scale bar, 50 μm.
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3.6. Genotyping
DNA was extracted from hES cell cultures using a Chemagen DNA
extraction robot according to the manufacturer's instructions. Ampliﬁ-
cation of polymorphic microsatellite markers was carried out as de-
scribed (Ilic et al., 2012). Allele sizes were recorded to give a unique
ﬁngerprint of each cell line.
3.7. Array comparative genomic hybridization (aCGH)
aCGH was performed as described in details (Ilic et al., 2012).
3.8. SNP array
SNP array was performed as described in details (Canham et al.,
2015).
3.9. HLA typing
HLA-A, -B and -DRB1 typing was performed with a PCR sequence-
speciﬁc oligonucleotide probe (SSOP; Luminex, Austin, TX, USA) hybrid-
ization protocol at the certiﬁed Clinical Transplantation Laboratory,
Guy's and St. Thomas' NHS Foundation Trust and Serco Plc. (GSTS) Pa-
thology (Guy's Hospital, London, UK) as described (Jacquet et al., 2013).
4. Author disclosure statement
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Fig. 2.Differentiation of three germ layers in vitro is conﬁrmed by detection of markers: smoothmuscle actin (red) formesoderm, β-III tubulin (red) for ectoderm andα-fetoprotein (red)
for endoderm. Nuclei are visualized with Hoechst 33342 (blue). Scale bar, 50 μm.
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